Graft Versus Host Disease Treatment Market Analysis and Growth Forecast by 2032
The global Graft Versus Host Disease (GvHD) Treatment Market is estimated to reach $5,655.37 million by 2032, growing at an 8.3% CAGR. Corticosteroids and combination therapy for graft-versus-host disease in HCT patients are increasing in popularity, strengthening the market for (GvHD) treatment. In 2022, the market is expected to be worth $2,547.86 million USD. The market grew at a 7.8% annual rate between 2016 and 2021. Allogeneic hematopoietic cell transplant patients may benefit from recent advancements in overall survival and acute graft-versus-host disease (GVHD) severity levels, however, there are a number of challenges that must be addressed. In addition, newer medications such as Jakafi and Rezurock have recently been approved for the prevention and treatment of chronic (GVHD) and may provide a greater benefit than older medications. For treating adults and pediatric patients with GVHD, Orencia (abatacept) was approved by the U.S. Food and Drug Administration in Decembe...